Once-weekly versus every-other-day stereotactic body radiotherapy in patients with prostate cancer (PATRIOT): A phase 2 randomized trial

Prostate stereotactic body radiotherapy (SBRT) regimens differ in time, dose, and fractionation. We completed a multicentre, randomized phase II study to investigate the impact of overall treatment time on quality of life (QOL). Men with low and intermediate-risk prostate cancer were randomly assign...

Full description

Saved in:
Bibliographic Details
Published in:Radiotherapy and oncology 2018-05, Vol.127 (2), p.206-212
Main Authors: Quon, Harvey C., Ong, Aldrich, Cheung, Patrick, Chu, William, Chung, Hans T., Vesprini, Danny, Chowdhury, Amit, Panjwani, Dilip, Pang, Geordi, Korol, Renee, Davidson, Melanie, Ravi, Ananth, McCurdy, Boyd, Zhang, Liying, Mamedov, Alexandre, Deabreu, Andrea, Loblaw, Andrew
Format: Article
Language:English
Subjects:
Aged
Dose Fractionation, Radiation
Gastrointestinal Diseases - etiology
Humans
Male
Patient Reported Outcome Measures
Prostatic neoplasms
Prostatic Neoplasms - radiotherapy
Quality of Life
Radiation Injuries - etiology
Radiosurgery
Radiosurgery - adverse effects
Radiosurgery - methods
Randomized controlled trial
Stereotactic body radiotherapy
Time Factors
Toxicity
Urination Disorders - etiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Prostate stereotactic body radiotherapy (SBRT) regimens differ in time, dose, and fractionation. We completed a multicentre, randomized phase II study to investigate the impact of overall treatment time on quality of life (QOL). Men with low and intermediate-risk prostate cancer were randomly assigned to 40 Gy in 5 fractions delivered once per week (QW) vs. every other day (EOD). QOL was assessed using the Expanded Prostate Cancer Index Composite. The primary endpoint was the proportion with a minimum clinically important change (MCIC) in bowel QOL during the acute (≤12 week) period, and analysis was by intention-to-treat. ClinicalTrials.gov NCT01423474. 152 men from 3 centres were randomized with median follow-up of 47 months. Patients treated QW had superior acute bowel QOL with 47/69 (68%) reporting a MCIC compared to 63/70 (90%) treated EOD (p = 0.002). Fewer patients treated QW reported moderate–severe problems with bowel QOL during the acute period compared with EOD (14/70 [20%] vs. 40/70 [57%], p 
ISSN:0167-8140
1879-0887
DOI:10.1016/j.radonc.2018.02.029